CAR Peptide Targeting for Endothelial Injury Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for COVID-19, such as corticosteroids, lack precision and specificity in targeting endothelial injury, leading to off-target effects and limited survival benefits in patients with sepsis and multi-organ failure.
Innovation Solution
Co-administration of a CAR peptide with low-dose hydrocortisone to selectively target and accumulate at sites of endothelial injury, enhancing the therapeutic effects of hydrocortisone and other drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids are administered to treat COVID-19 patients with endothelial injury, then anti-inflammatory effects are achieved, but off-target effects and lack of precision occur
Solution Approach 1:
The CAR peptide acts as an intermediary that binds to both the damaged endothelium and corticosteroids, facilitating selective delivery of the drug to the target site. This mediator approach allows the corticosteroid to reach injured tissues precisely while minimizing exposure to healthy tissues, thereby reducing off-target effects while maintaining therapeutic efficacy.
2Object-affected harmful factors
If corticosteroids are used to reduce inflammatory-induced lung injury, then some therapeutic benefit is achieved, but mortality improvement is limited
Solution Approach 1:
The CAR peptide enables local quality by concentrating corticosteroids specifically at sites of endothelial injury in the lungs and other affected organs. This localized delivery ensures that anti-inflammatory effects are maximized precisely where needed (injured tissues) while avoiding systemic suppression of immune function in healthy areas, thereby improving mortality outcomes without compromising overall immune defense.
3Object-generated harmful factors
If hydrocortisone is administered to treat sepsis, then anti-inflammatory effects are achieved, but precision in targeting injured vascular endothelium is insufficient
Solution Approach 1:
The CAR peptide serves as a targeting intermediary that recognizes specific markers on injured vascular endothelium and delivers hydrocortisone precisely to these sites. This intermediary mechanism transforms non-selective systemic hydrocortisone administration into a targeted therapy that accumulates at injured vessels, achieving both anti-inflammatory effects and high targeting precision simultaneously.
4Object-generated harmful factors
If corticosteroids are used to treat COVID-19 patients, then inflammatory response is suppressed, but immune suppression and other side effects occur
Solution Approach 1:
The CAR peptide enables local quality by directing corticosteroids specifically to sites of endothelial injury where inflammatory response needs suppression. This localized delivery creates a gradient of drug concentration with high levels at injured sites and low levels systemically, thereby suppressing harmful inflammation locally while preserving immune function systemically and avoiding side effects like immune suppression, myopathy, and hyperglycemia.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Improves survival rates and reduces endothelial damage by delivering corticosteroids precisely to injured tissues, minimizing side effects and increasing the efficacy of co-administered drugs.
Implementation Method 1
Co-administration of a CAR peptide with low-dose hydrocortisone to selectively target and accumulate at sites of endothelial injury
Data Source
AI summary
A conjugate for treating an individual suffering from a disease, wherein the conjugate is comprised of: a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; and at least one therapeutic molecule and methods for making and administering same. Also disclosed is a combination product for use in the treatment of a disease, wherein the combination product comprises: (a) a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; (b) a liposome, wherein the targeting peptide is encapsulated within the liposome; and (c) an effective amount of an anti-inflammatory agent and methods for making and administering same.